




INVESTORS PRÉSENTATION


18-19th April 2017

Smallcap Event

One-to-One BtoB Group Meetings Conferences Pitches Round Tables

CONFIDENTIAL





THE EXCELLENCE OF CERAMICS FOR THE TREATMENT OF BONE INFECTIONS AND BONE METASTASES



André KERISIT

- Chairman and Founder of I.CERAM Group
- More the 30 years of experience in the field of orthopedics



Christophe DURIVAULT

- Chief Financial Officer of I.CERAM Group
- More the 13 years of experience in the field of business planning and fund rising
- Ceramics engineer

R&D



Dr Eric DENES, M.D
Infectious Diseases Specialist / Scientific Director

- Expert referent in antibiotherapy
- Bone and joint infection specialist
- Multidisciplinary team for bone and joint infections
- More than 60 scientific publications
- Member of ESCMID, SPLIF



G. BARRIERE, PhD
Biology







E. POLI, PhD
Chemistry



G. LEVEQUE, PhD
Ceramic

OUR IMPLANTATIONS IN 2017



-  Head Office
-  Branches
-  Distributors

Our fundamentals

100% internal production by using our own industrial capabilities

15 millions Euros Turn Over

A presence in 8 countries of which 2 branches

85 000 products sold without mat erio-vigilance

Orthopaedics, Neurosurgery and Thoracic Surgery



World premiere on 19th of March 2015: Sternoctomy of a metastasis by using a ceramic implant

Company establishment at Limoges in 2005
Ester Technopole / The European Ceramics Centre

A unique know-how in AL_2O_3 ceramics

Our internal expertise



Distribution

- Direct selling in France: 10 commercials
- 2 Branches
- Exclusive or Non-Exclusive Distributors

Sterilizing

- Packaging
- White room ISO 7

Certification

- Products
- Management
- Process validation

Fabrication

- 40 employees : mechanical production centre
- Ceramics Laboratory
- Chemical and Biological Laboratory

Design

- Independent scientific committee
- 30% of TO re-invested in R&D
- Internally managed scientific expertise: 8 doctors and engineers

Listening

- A close relationship with surgeons
- From your ideas to the creation of the product

Continuous Innovation



CERAMIL PATENT
Bioceramics

AKILE TAP
PATENT
Ankle




BIRDIE
PATENT
Spine



BIFIX PATENT
Cephalic Screw
Patent pending

STERNUM
PATENT
Patent pending



2001

2006

2007

2008


2014

2015

ISIS
PATENT
Hip



Tn'R PATENT
Hip



Ceramic + HAP
Bioceramic




Ceramic + GEL
PATENT
In progress

JOINT ARTHROPLASTY

OSTEOSYNTHESIS

POROUS CERAMIC



A WORLD CLASS SCIENTIFIC COMMITTEE

Experts from the medical environment

Internationally renown and respected

Grouping of 9 medical specialties

RESEARCHER

Genetics

Dr Frank STURTZ

- Head, Dept of Biochemistry and Molecular Genetics, Dupuytren Hospital Limoges
- Founder of Medincell
- Specialist in therapeutic delivery of gel

Pharmacy

Pr Marylène VIANA

- Galenic pharmacy
- Faculty of Pharmacy of Limoges
- Area of expertise: design of pharmaceuticals, provision of active ingredients

Organic Chemistry

Pr Vincent SOL

- Director of the Laboratory of Chemical and Natural substances, EA 1069
- GDR CNRS 3049: Photoactivable-Photochemiotherapy Pharmaceuticals (PHOTOMED), GDR CNRS/INRA BioMatPro

PRACTITIONERS

Orthopedics Surgery

Dr Fabrice Fiorenza

- Surgeon, Orthopedics-Traumathology at CHRU Limoges
- Specialist on surgical treatment of bones tumors

Dr Daniel SETTON

- Surgeon, Orthopedics-Traumatology
- Former head of CHRU Clinic of Limoges
- Emaillieurs –Colombier Clinic of Limoges

Cardiovascular Surgery

Dr François BERTIN

- Thoracic and Vascular Surgeon at CHRU Limoges

Infectiology

Dr Eric DENES

- Hospital practitioner
- Specialized in infectious and tropical diseases
- Specialist in antibiotics

Pharmacology

Dr Christian WOLOCH

- Hospital practitioner, Pharm D, PhD
- Dept of Pharmacology, Toxicology and Pharmacovigilance
- Centre for Biological and Health Research (CBRS) CHRU Limoges

EXPERTS

Animal Health

Dr Christian MAGE

- Specialized in animal health
- Expert in Pharmacy
- Expertise in AMM approvals (approval of marketing of new pharma products)

Microbiology

Dr Tan-sothea OUK

- Lecturer
- Biological Engineering Dept of IUT Limousin
- Areas of expertise: Cell Biology, Microbiology, Analytical Chemistry


i.ceram : Une solution chirurgicale thérapeutique INNOVANTE

Evolution de la chirurgie : Généralisation de la chirurgie micro-invasive et ambulatoire

1950



1980



1990



2005



2015



2020



I.CERAM : experts IN BIOCERAMICS


CERAMIL PRODUCTS' RANGE :

- CERVICAL CAGE
- BLOCKS FOR CERVICAL CORPORECTOMY
- INTERSOMATIC CYLINDRE (CLOWARD TECHNIQUE)
- INCLINED CERVICAL CAGE
- TREPAN CAPS
- LUMBAR CAGE
- TIBIAL OSTEOTOMY WEDGE
- DIEDRAL WEDGE
- CALCANEUM WEDGE

CERAMIL
POROUS CELLULAR
ALUMINA
 Al_2O_3



THE RANGE OF POROUS CELLULAR ALUMINA
BIOCERAMIC




POROSITY OF ALUMINA BIOCERAMICS



HUMAN BONE POROSITY

2015 :The first world PREMIERE implantation OF a CERAMIC sternum




20H DU 23/06/15



MATINALE 24/06/15



MATINALE 25/06/15




CHU de Limoges – 19 mars 2015 - Opération done by Dr François Bertin



- A LOSS OF THE RISK OF INFECTION,
- A DURABLE BONE INTEGRATION,
- A REDUCTION OF THE TIME OF OPERATION,
- A MECHANICAL RESISTANCE PERFECTLY MANAGED,
- A REGAINED PLASTICITY OF THE THORAX,
- A QUALITY OF LIFE FOR THE PATIENT.

Material colonisation



H+2
Adhesion

H+4
Beginning of
biofilm formation

H+8
Biofilm over all the
surface


H+24
Bacteria release

I.CERAM : Une Rupture thérapeutique sur ce marché



IMPLANT
CÉRAMIQUE



IMPLANT CÉRAMIQUE
+ ANTI-INFECTIEUX






Zone métastatique
ou infectée




LE PREMIER IMPLANT OSSEUX ACTIF

In vitro release




Contribution of porous ceramic >> Surgery

Pro
Low
Pos
Act:



Amount of *S. aureus* adherent to different materials






Indications

Infection



Tumor



In vivo release

Preliminary results

Local dosages

Samples in Redon drains placed above muscle flap (not directly in contact of the sternal prosthesis)

H1 : 1400 mg/L (i.e. 175 times the dose required for an MCI of 1 μ g/ml)

H24 : 395 mg/L (i.e. 50 times the dose required for an MCI of 1 μ g/ml)

Blood samples

No detection of gentamicin from H1 to H48 for 2 patients


The seven first implantations OF a CERAMIC sternum

	Sex	Age (years)	Indication	Risk factors	Body mass Index	ASA	Type of surgery	Operation time (Hours)	Complications	Delay to discharge after surgery (Days)	Follow up (Months)
1	F	55,1	Radio-induced sarcoma	Malignancy	22,5	3	Complete replacement	4	None	41	22
2	F	53,9	Breast cancer metastasis & skin localisation following a biopsy	Malignancy, Diabetes mellitus	24,6	3	Complete replacement	6	Hematoma	36	15
3	M	61,5	Sternal disunion after aortic valve replacement	Lung cancer with radiotherapy including sternal area (2007), Diabetes mellitus, Active smoker (55PA), COPB	26,3	4	Complete replacement	4	Surgical site infection without prosthesis infection	132	17
4	F	37,9	Manubrial breast cancer metastasis	Malignancy, Tabac (40PA)	19,3	3	Hemi-sternum replacement	2,5	None	19	10
5	M	68,1	Sternal disunion after coronary bypass and deep sternal wound infection	Diabetes mellitus, obesity, COPB	29,8	3	Complete replacement	4	None	20	7
6	M	77,8	Sternal disunion after coronary bypass and deep sternal wound infection	Diabetes mellitus, obesity, COPB, HTA, Prostate cancer	32,6	3	Complete replacement	2	None	25	3
7	F	41,9	Clavicle and manubrium neoplasia	Malignancy	21,9	3	Hemi-sternum replacement	2	None	5	2

Nowadays




Tomorrow




FUTUR OF PRODUCTS I.CERAM


- Développements
- Actual Products



3 – Les METASTASES OSSEUSES



Les sites privilégiés des métastases osseuses



STATISTIQUES DES SOCIÉTÉS COTÉES SUR ALTERNEXT

Voici les statistiques des sociétés dans le domaine de l'orthopédie par évolution du cours (rang ICERAM : 1/12):

Nom société	Date introduction	Montant IPO	Cours introduction	Montant total levées	Capitalisation au 12/04/2017	Cours au 12/04/2017	Evolution cours	Ratio Capitalisation sur Montants levés
Iceram	19-déc-2014	2 700 000 €	4.65 €	14 108 000.00 €	37 651 949 €	7.05 €	52%	2.67 €
Vexim	26-avr-2012	11 000 000 €	9.50 €	25 400 000.00 €	95 527 366 €	11.89 €	25%	3.76 €
Medicrea	23-juin-2006	11 600 000 €	6.15 €	35 000 000.00 €	59 522 778 €	5.70 €	-7%	1.70 €
Amplitude	02-juil-2015	106 100 000 €	5.00 €	106 100 000.00 €	139 286 982 €	4.01 €	-20%	1.31 €
Pixium Vision	17-juin-2014	34 500 000 €	8.00 €	50 400 000.00 €	67 290 112 €	5.90 €	-26%	1.34 €
Spineguard	23-avr-2013	8 100 000 €	7.29 €	33 600 000.00 €	23 244 346 €	4.20 €	-42%	0.69 €
Bone therapeutics	06-févr-2015	32 200 000 €	16.00 €	98 650 000.00 €	46 587 661 €	7.40 €	-54%	0.47 €
Safe Orthopedics	06-févr-2015	9 600 000 €	2.55 €	23 200 000.00 €	19 170 079 €	1.40 €	-45%	0.83 €
Spineway	13-févr-2013	4 900 000 €	7.47 €	4 900 000.00 €	10 873 556 €	2.93 €	-61%	2.22 €
Crossject	20-févr-2014	17 400 000 €	10.50 €	44 400 000.00 €	55 093 846 €	5.19 €	-51%	1.24 €
Stentys	22-oct-2010	23 000 000 €	12.00 €	95 300 000.00 €	43 623 701 €	2.47 €	-79%	0.46 €
Implanet	25-nov-2013	14 100 000 €	7.00 €	83 700 000.00 €	10 062 000 €	0.78 €	-89%	0.12 €

LES DONNÉES BOURSIÈRES D'ICERAM

Identification:

ISIN: FR0011511971

Mémo: ALICR

Nombre de titres : 5 340 702

Secteur d'activité : Technologies
médicales

Indice principal : Alternext All-Share

Marché : Alternext

Place de cotation : Euronext Paris
(France)

Eligibilité PEA : Oui

Eligibilité PEA PME : Oui

Actionnariat:

• **Investissement et Développement :**
55,92%


• **Flottant :** 33,99%

• **Investisseurs privés :** 9,51%

• **Autocontrôle :** 0,38%

Cours au 12/04/17: 7,05 €

Calendrier des actions :



STATISTIQUES DES SOCIÉTÉS COTÉES SUR ALTERNEXT

Voici les statistiques des sociétés dans le domaine de l'orthopédie par montant levés (rang ICERAM : 11/12):

Nom société	Date introduction	Montant IPO	Cours introduction	Montant total levés	Capitalisation au 12/04/2016	Cours au 12/04/2016	Evolution cours	Ratio Capitalisation sur Montants levés
Amplitude	02-juil-2015	106 100 000 €	5.00 €	106 100 000.00 €	139 286 982 €	4.01 €	-20%	1.31 €
Bone therapeutics	06-févr-2015	32 200 000 €	16.00 €	98 650 000.00 €	46 587 661 €	7.40 €	-54%	0.47 €
Stentys	22-oct-2010	23 000 000 €	12.00 €	95 300 000.00 €	43 623 701 €	2.47 €	-79%	0.46 €
Implanet	25-nov-2013	14 100 000 €	7.00 €	83 700 000.00 €	10 062 000 €	0.78 €	-89%	0.12 €
Pixium Vision	17-juin-2014	34 500 000 €	8.00 €	50 400 000.00 €	67 290 112 €	5.90 €	-26%	1.34 €
Crossject	20-févr-2014	17 400 000 €	10.50 €	44 400 000.00 €	55 093 846 €	5.19 €	-51%	1.24 €
Medicrea	23-juin-2006	11 600 000 €	6.15 €	35 000 000.00 €	59 522 778 €	5.70 €	-7%	1.70 €
Spineguard	23-avr-2013	8 100 000 €	7.29 €	33 600 000.00 €	23 244 346 €	4.20 €	-42%	0.69 €
Vexim	26-avr-2012	11 000 000 €	9.50 €	25 400 000.00 €	95 527 366 €	11.89 €	25%	3.76 €
Safe Orthopedics	06-févr-2015	9 600 000 €	2.55 €	23 200 000.00 €	19 170 079 €	1.40 €	-45%	0.83 €
Iceram	19-déc-2014	2 700 000 €	4.65 €	14 108 000.00 €	37 651 949 €	7.05 €	52%	2.67 €
Spineway	13-févr-2013	4 900 000 €	7.47 €	4 900 000.00 €	10 873 556 €	2.93 €	-61%	2.22 €



IMPLANTS DE HAUTE TECHNOLOGIE

THANK YOU FOR YOUR ATTENTION

<http://www.iceram.fr/>

CONFIDENTIEL

I.CERAM est présent :

